OSlms: A Web Server to Evaluate the Prognostic Value of Genes in Leiomyosarcoma

The availability of transcriptome data and clinical annotation offers the opportunity to identify prognosis biomarkers in cancer. However, efficient online prognosis analysis tools are still lacking. Herein, we developed a user-friendly web server, namely Online consensus Survival analysis of leiomyosarcoma (OSlms), to centralize published gene expression data and clinical datasets of leiomyosarcoma (LMS) patients from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). OSlms comprises of a total of 268 samples from three independent datasets, and employs the Kaplan Meier survival plot with hazard ratio (HR) and log rank test to estimate the prognostic potency of genes of interests for LMS patients. Using OSlms, clinicians and basic researchers could determine the prognostic significance of genes of interests and get opportunities to identify novel potential important molecules for LMS. OSlms is free and publicly accessible at http://bioinfo.henu.edu.cn/LMS/LMSList.jsp.

[1]  Philippe Terrier,et al.  RNA sequencing validation of the Complexity INdex in SARComas prognostic signature. , 2016, European journal of cancer.

[2]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[3]  Jilong Yang,et al.  The prognostic role of PRUNE2 in leiomyosarcoma , 2013, Chinese journal of cancer.

[4]  Dennis B. Troup,et al.  NCBI GEO: mining millions of expression profiles—database and tools , 2004, Nucleic Acids Res..

[5]  Yusuke Nakamura,et al.  Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors , 2016, International journal of oncology.

[6]  Steven J. M. Jones,et al.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas , 2017, Cell.

[7]  Kenta Nakai,et al.  PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.

[8]  Xiangqian Guo,et al.  Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment , 2017, BMC Cancer.

[9]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[10]  Emmanuel Barillot,et al.  ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis , 2005, Nucleic Acids Res..

[11]  Helen E. Parkinson,et al.  ArrayExpress—a public database of microarray experiments and gene expression profiles , 2006, Nucleic Acids Res..

[12]  C. Blomqvist,et al.  Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group , 2007, Cancer.

[13]  Mårten Fernö,et al.  Soft tissue leiomyosarcoma. A population‐based epidemiologic and prognostic study of 48 patients, including cellular dna content , 1992, Cancer.

[14]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[15]  Jin-Hee Ahn,et al.  High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers , 2015, Virchows Archiv.

[16]  M. Bianchi,et al.  HMG proteins: dynamic players in gene regulation and differentiation. , 2005, Current opinion in genetics & development.

[17]  Trevor Hastie,et al.  Clinically Relevant Molecular Subtypes in Leiomyosarcoma , 2015, Clinical Cancer Research.

[18]  Alex Boussioutas,et al.  Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients , 2016, Oncotarget.

[19]  Fan Yang,et al.  High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer , 2015, Tumor Biology.

[20]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[21]  J. Blay,et al.  Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity , 2010, Nature Medicine.

[22]  M. Ohira,et al.  Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in human neuroblastomas , 2006, Oncogene.

[23]  Herbert S Schwartz,et al.  Prognostic significance of c-Myc expression in soft tissue leiomyosarcoma , 2009, Modern Pathology.

[24]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.